Last reviewed · How we verify
AP 12009 10 µM
AP 12009 is an antisense oligonucleotide that inhibits transforming growth factor-beta 2 (TGF-β2) expression to reduce immunosuppression and promote anti-tumor immunity.
AP 12009 is an antisense oligonucleotide that inhibits transforming growth factor-beta 2 (TGF-β2) expression to reduce immunosuppression and promote anti-tumor immunity. Used for Glioblastoma, Pancreatic cancer.
At a glance
| Generic name | AP 12009 10 µM |
|---|---|
| Sponsor | Isarna Therapeutics GmbH |
| Drug class | Antisense oligonucleotide |
| Target | TGF-β2 mRNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AP 12009 targets TGF-β2 mRNA, reducing production of this immunosuppressive cytokine in the tumor microenvironment. By decreasing TGF-β2 levels, the drug aims to relieve immune suppression and enhance the body's natural anti-tumor immune response. This mechanism is particularly relevant in cancers where TGF-β2 contributes to immune evasion and tumor progression.
Approved indications
- Glioblastoma
- Pancreatic cancer
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Headache
Key clinical trials
- Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma (PHASE3)
- Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AP 12009 10 µM CI brief — competitive landscape report
- AP 12009 10 µM updates RSS · CI watch RSS
- Isarna Therapeutics GmbH portfolio CI